Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds

Merck's experimental oral PCSK9 inhibitor, enlicitide, demonstrated significant efficacy in Phase 3 trials, achieving up to a 60% reduction in LDL cholesterol after 24 weeks when added to statin therapy for patients with high cholesterol and cardiovascular risk. This development addresses a significant unmet medical need for patients whose cholesterol is not adequately controlled by statins alone, offering a convenient oral alternative to existing injectable PCSK9 inhibitors. With a safety profile comparable to placebo, Merck plans to seek U.S. FDA approval early next year, positioning enlicitide to potentially expand treatment options in the cardiovascular market.

Analysis

Merck's investigational oral PCSK9 inhibitor, enlicitide, demonstrated significant efficacy in Phase 3 trials, achieving up to a 60% reduction in LDL cholesterol over 24 weeks when added to statin therapy. This positions enlicitide as a potential first-in-class oral option for patients with high LDL cholesterol and cardiovascular risk who are inadequately managed by statins alone, addressing a critical unmet medical need. The drug also showed reductions of 53% in non-HDL cholesterol, 50% in ApoB, and 28% in lipoprotein(a).

The safety profile of enlicitide appears favorable, with serious adverse events occurring in approximately 10% of the treatment group, comparable to the 12% observed in the placebo arm. Merck plans to submit enlicitide for US FDA approval early next year, indicating confidence in the trial data and a clear path towards commercialization. This regulatory timeline suggests a potential market entry within the next 1-2 years, pending approval.

While injectable PCSK9 inhibitors are already on the market, enlicitide's oral formulation offers a significant convenience advantage, potentially expanding patient adherence and market penetration. The drug's distinct mechanism of action, complementary to statins, provides a robust rationale for its additive efficacy in a patient population where current therapies are often insufficient. This oral delivery could differentiate Merck in the competitive cardiovascular disease market.

Key Decisions for Investors

• Investors should consider the strong Phase 3 data for enlicitide as a significant positive for Merck's pipeline, potentially enhancing long-term revenue growth in the cardiovascular segment.
• Monitor the FDA approval timeline for enlicitide, as its oral formulation could capture substantial market share from existing injectable PCSK9 inhibitors and address a large, underserved patient population.
• Assess potential competitive responses from companies with existing PCSK9 inhibitors and the eventual pricing strategy for enlicitide, which will influence its market penetration and profitability.